Red Hat, Inc. (NYSE:RHT), the world's leading provider of open source
solutions, today introduced updates for Red Hat Enterprise Linux
OpenStack Platform 5, the latest version of its enterprise-ready
OpenStack platform built with the latest Icehouse community release.
BOSTON, MA and SAN FRANCISCO, CA --
CSC), a global leader in next-generation IT services and solutions,
today announced the next generation of CSC’s Agility
Platform ™ 9.2 with new capabilities that make it easier for clients
to manage large cloud service portfolios, order customizable hybrid
cloud services, and extend a self-service IT delivery model to more end
users across the enterprise.
Provides Investors Direct Access to High-Caliber, Institutional Quality Public and Private Investment Offerings "We Are Crowdfunding" Internet-Based Investment Platform Leverages RCAP's Existing Broker-Dealer Infrastructure Including Investment Banking, Due Diligence, Compliance and Research
"We Are Crowdfunding" Provides Unique Opportunity for Financial Advisors to Connect with High Quality Retail Investors Powered by Trupoly Technology, Offering Intuitive User Experience and Open Architecture Platform NEW YORK , Sept.
Acquires Assets of Trupoly, White-Label Investor Relationship Management Portal and Adds Key Executives to Crowdfunding Initiative Crowdfunding Platform to Leverage RCS Capital Expertise in Investment Identification, Research, Due Diligence, Compliance, Structuring and Management
NEW YORK , July 21, 2014 /PRNewswire/ -- RCS Capital Corporation ("RCAP") (NYSE: RCAP) , announced today that it is establishing a crowdfunding investment platform which it will brand under the name, "We R Crowdfunding." In connection with this initiative, RCAP acquired substantially all of the assets of New York based Trupoly, Inc., a white-label investor relationship management portal, which will be integrated into RCAP's new crowdfunding investment platform.
New Applications Announced for Proprietary CombiPlex Platform Geared Towards Molecularly Targeted Therapies
CPX-351 to be Explored in Additional Patient Populations, Including New Acute Myeloid Leukemia (AML) Subsets and Other Hematologic Malignancies
EWING, N.J., July 17, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) , a pharmaceutical company developing new and more effective therapies to treat cancer, today will present updates on its lead candidate CPX-351 and CombiPlex ® technology platform at its Analyst Day meeting for analysts and investors.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.